The stock's rise snapped a five-day losing streak.

Shares of Regeneron Pharmaceuticals, Inc. REGN have gained 13.5% in the year so far against the industry’s decline of 2.8%.

Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy ...

For the biopharma industry to match the pace of genomic innovations and speed new therapies to market, it will need to ...

7 March 2022 Regeneron has failed to convince a Manhattan district court to drop a lawsuit claiming that it developed ...

Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) ...

Regeneron Pharmaceuticals (REGN) said it currently expects that financial results for the third quarter 2024 will include an acquired ...

Breast cancer is the most common form of the disease diagnosed among women in the United States and decades of work in education, research and treatment played an ...

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

Regeneron's CSO George Yancopoulos warns that GLP-1 weight-loss drugs like Ozempic may lead to rapid muscle loss, increasing ...

Activist investor Starboard Value has taken a roughly $1 billion stake in Pfizer and wants the drugmaker to make changes ...

Regeneron Pharmaceuticals expects to book a $56 million pretax charge related to collaboration and licensing agreements. The Westchester County, New York-based biotechnology company said Monday it ...